Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price
Drug Information: A Guide for Pharmacists, Fourth Edition ISE

Drug Information: A Guide for Pharmacists, Fourth Edition ISE

International Standard Edition - lower price

9780071768191
115.92 zł
110.12 zł Save 5.80 zł Tax included
Lowest price within 30 days before promotion: 110.12 zł
Quantity
Product unavailable
Out of print

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Everything pharmacists need to know about drug information management

Drug Information:: A Guide for Pharmacists, Fourth Edition teaches students and professionals how to research, interpret, evaluate, collate, and disseminate drug information in the most effective and efficient manner possible. Updated throughout, the book also addresses other important issues such as the legal and ethical considerations of providing information, how to respond to requests for information, and how to determine what information should be made available.

Drug Information:: A Guide for Pharmacists, Fourth Edition covers essential topics such as::

  • Formulating effective responses and recommendations for information
  • Evaluation of drug literature
  • The application of statistical analysis in the biomedical sciences
  • Drug evaluation monographs
  • Adverse drug reactions
  • Medication and patient safety
  • Investigational drugs

New to this edition::

  • Five new chapters:: “Policy Development, Project Design, and Implementation,” “Drug Information in Ambulatory Care,” “Drug Information and Contemporary Community Pharmacy Practice,” “Drug Information Education and Training,” and “Pharmaceutical Industry and Regulatory Affairs:: Opportunities for Drug Information Specialists”
  • Key Concepts have been added to the beginning of each chapter and are identified with icons in the chapter text
  • Case Studies and multiple-choice questions have been added to most chapters
Twenty-two appendices include:: Drug Consultation Request Form,Performing a PubMed® Search, Questions for Assessing Clinical Trials, and Questions to Consider for Critique of Primary Literature.
Product Details
McGraw Hill / Medical
10369
9780071768191

Data sheet

Publication date
2011
Issue number
4
Cover
paperback
Pages count
1192
Dimensions (mm)
152 x 229
  • Chapter One. Introduction to the Concept of Medication Information
    Mary Lea Gora-Harper and J. Russell May
    Chapter Two. Formulating Effective Responses and Recommendations:: A Structured Approach
    Karim Anton Calis and Amy Heck Sheehan
    Chapter Three. Drug Information Resources
    Kelly M. Shields and Elaine Blythe
    Chapter Four. Literature Evaluation I:: Controlled Clinical Trial Evaluation
    Michael Kendrach, Maisha Kelly Freeman, Terri M. Wensel, and Peter J. Hughes
    Chapter Five. Literature Evaluation II:: Beyond the Basics
    Patrick J. Bryant, Karen P. Norris, Cydney E. McQueen, and Elizabeth A. Poole
    Chapter Six. Pharmacoeconomics
    James P. Wilson and Karen L. Rascati
    Chapter Seven. Evidence-Based Clinical Practice Guidelines
    Kevin G. Moores
    Chapter Eight. The Application of Statistical Analysis in the Biomedical Sciences
    Ryan W. Walters and Karen L. Kier
    Chapter Nine. Professional Writing
    Patrick M. Malone
    Chapter Ten. Legal Aspects of Drug Information Practice
    Martha M. Rumore
    Chapter Eleven. Ethical Aspects of Drug Information Practice
    Linda K. Ohri
    Chapter Twelve. Pharmacy and Therapeutics Committee
    Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, and Paul J. Nelson
    Chapter Thirteen. Drug Evaluation Monographs
    Patrick M. Malone, Nancy L. Fagan, Mark A. Malesker, Paul J. Nelson, and Linda K. Ohri
    Chapter Fourteen. Quality Improvement and the Medication Use Process
    Mark A. Ninno and Sharon Davis Ninno
    Chapter Fifteen. Medication Misadventures I:: Adverse Drug Reactions
    Philip J. Gregory and Zara Risoldi Cochrane
    Chapter Sixteen. Medication Misadventures II:: Medication and Patient Safety
    Kathryn A. Crea
    Chapter Seventeen. Investigational Drugs
    Bambi Grilley
    Chapter Eighteen. Policy Development, Project Design, and Implementation
    Stacie Krick Evans
    Chapter Nineteen. Drug Information in Ambulatory Care
    Debra L. Parker
    Chapter Twenty. Drug Information and Contemporary Community Pharmacy Practice
    Morgan L. Sperry and Patricia A. Marken
    Chapter Twenty-One. Drug Information Education and Training
    Kelly M. Smith
    Chapter Twenty-Two. Pharmaceutical Industry and Regulatory Affairs:: Opportunities for Drug Information Specialists
    Jean E. Cunningham and Lindsay E. Davison
    Appendix 2-1. Drug Consultation Request Form
    Appendix 2-2. Sample Questions for Obtaining Background Information From Requestors
    Appendix 3-1. Performing a PubMed Search
    Appendix 3-2. Selected Primary Literatures Sources
    Appendix 4-1. Questions for Assessing Clinical Trials
    Appendix 5-1. Beyond the Basics:: Questions to Consider for Critique of Primary Literature
    Appendix 7-1. New Zealand Guidelines Group (NZGG)
    Appendix 7-2. National Institute for Clinical Excellence (NICE)
    Appendix 7-3. National Institute for Clinical Excellence (NICE) Topic Selection Criteria
    Appendix 7-4. Study Selection Process—Centre for Reviews and Dissemination (CRD)
    Appendix 7-5. Study Selection Points—Centre for Reviews and Dissemination (CRD)
    Appendix 7-6. Data Synthesis—Centre for Reviews and Dissemination (CRD)Appendix 7-7. National Institute for Clinical Excellence (NICE)—Evidence Table Format for Intervention Studies
    Appendix 7-8. New Zealand Guidelines Group (NZGG)—Considered Judgment
    Appendix 7-9. Guidelines Advisory Committee (GAC) —Levels of Evidence Grades of Recommendation
    Appendix 7-10. National Institute for Clinical Excellence (NICE) Guideline Structure
    Appendix 7-11. Scottish Intercollegiate Guidelines Network (SIGN) Consultation and Peer-Review
    Appendix 7-12. Grades of Recommendation Assessment Development and Evaluation (GRADE) System Advantages
    Appendix 7-13. Appraisal of Guidelines Research & Evaluation (AGREE) Instrument
    Appendix 7-14. Conference on Guideline Standardization (COGS) Checklist
    Appendix 7-15. Implementation Strategies
    Appendix 9-1. Question Example
    Appendix 9-2. Abstracts
    Appendix 9-3. Bibliography
    Appendix 11-1. Code of Ethics for Pharmacists
    Appendix 12-1. Pharmacy and Therapeutics Committee Procedure
    Appendix 12-2. Formulary Request Form
    Appendix 12-3. P&T Committee Meeting Attributes
    Appendix 12-4. Example P&T Committee Minutes
    Appendix 12-5. Chairperson Skills
    Appendix 12-6. Conflict-of-Interest Declaration
    Appendix 13-1. Format for Drug Monograph
    Appendix 13-2. Example Drug Monograph
    Appendix 14-1. Comparison of Quality Assurance and Total Quality Management in Health Care
    Appendix 14-2. Tools Used in Quality Improvement
    Appendix 14-3. Examples of Approaches to Quality Improvement
    Appendix 14-4. Example of a Quality Improvement Activity Plan
    Appendix 14-5. Example Report—Prescriber-Specific Results
    Appendix 14-6. Example of MUE Results
    Appendix 14-7. Quality Evaluation:: Response to Drug Information Request
    Appendix 15-1. Kramer Questionnaire
    Appendix 15-2. Naranjo Algorithm
    Appendix 15-3. Jones Algorithm
    Appendix 15-4. MedWatch Form
    Appendix 17-1. Investigational New Drug Application
    Appendix 17-2. Statement of Investigator
    Appendix 17-3. Protocol Medication Economic Analysis
    Appendix 17-4. Investigational Drug Accountability Record
    Appendix 18-1. High-Alert Medications
    Appendix 18-2. Medication Shortages and Backorders
    Appendix 19-1. FDA Guidelines for Proper Medication Disposal
    Appendix 22-1. Response Letter:: Drug A—Incidence of Yellow Stripes
    Glossary
    Answers for Case Studies
    Answers for Self-Assessment Questions
    Index
Comments (0)

  • Frequently purchased together

    No products available